This formal registration with the UK's data protection regulator confirms that our organisation processes personal data lawfully and transparently.
Aridhia's published papers and reports — SATRE specification scoring, DARE UK TREvolution, rare disease drug development, and TRE infrastructure research.
Delivering Regulatory Impact from Consortium-Based Projects
How consortium-based drug development programmes achieve regulatory milestones. Lessons from C-Path, IHI, and the RDCA-DAP platform built on the Aridhia DRE.
MIDD innovations for paediatric rare disease drug development, addressing small populations and patient heterogeneity. Published Clin Pharmacol Ther, 2025
Consideration of the Root Causes in Candidate Attrition During Oncology Drug Development
Oncology candidates fail at twice the rate of other therapeutic areas. This paper examines root causes of attrition from first-in-human through to registration.
How a DRE-enabled patient swarm approach incorporates the patient voice into collaborative QSP model development for Parkinson's disease across academic centres
Artificial Intelligence Opportunities to Guide Precision Dosing Strategies
How AI guides precision dosing, therapeutic drug monitoring, biomarker integration and individualised pharmacotherapy. Published J Pediatr Pharmacol Ther, 2024.
A beginner's guide for clinical pharmacologists entering rare disease drug development. Published in Clinical and Translational Science, 2025
The GOSH Aridhia DRE Partnership
How GOSH and Aridhia partnered in 2017 to build a state-of-the-art Digital Research Environment, now supporting 400+ active research and clinical projects.
Data federation in a trusted research environment
This whitepaper covers the concept of data federation within a trusted research environment by using the example of Aridhia’s work with the PHEMS consortium.
